Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Is Moderna a Warren Buffett Stock?

Pfizer

The writing could already be on the wall.

3 Big Hints That COVID Vaccine Booster Doses Are on the Way

Moderna (NASDAQ:MRNA) shares are trading lower on reports suggesting the company is having supply issues. According to a Reuters report, the company said that it does not have a sufficient stock of vaccines in storage to smooth shortfalls or delays and said the current delay can lead to short-term adjusting in the coming 2-4 weeks.

Why Moderna Shares Dipped On Tuesday

The FDA requested a larger clinical trial for the company's vaccine in younger kids.

Why Moderna Stock Slipped Today

BioNTech SE

The studies aim to spot rare side effects of the COVID-19 vaccine in younger recipients.

Pfizer and Moderna expanding vaccine studies in children 5 to 11, report says

The vaccine makers were reportedly asked by the Food and Drug Administration to expand the size of their ongoing trials.

Pfizer And Moderna Reportedly Expanding Covid Vaccine Studies Of Children To Better Understand Rare Side Effects

Moderna confirmed to CNBC on Monday it plans to expand the size of its clinical trial testing its Covid-19 vaccine in kids ages 5 to 11.

Moderna says it plans to expand Covid vaccine trial for kids 5 to 11, will seek FDA OK as early as year end

Pfizer Inc (NYSE:PFE) – BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) will expand the size of ongoing COVID-19 vaccine trials in children ages five to 11 to detect potential rare side effects, The New York Times reports. What Happened: The trial expansions come at the urging of the FDA, a precautionary measure designed to detect rare side effects, including heart inflammation problems that turned up in vaccinated people younger than 30.

FDA Asks Pfizer/BioNTech, Moderna To Expand COVID-19 Vaccine Trials In Children: NYT

Citi's Andrew Baum also thinks chances are good that annual boosters will be needed, even if risk of the disease drops.

Covid Boosters Are Coming This Year for People 50 and Older, Analyst Predicts

The shares of Moderna Inc (NASDAQ: MRNA) have received a price target increase from $228 to $299 from Goldman Sachs. These are the details.

MRNA Stock: $299 Target From Goldman Sachs

Once again, their high efficacy could mean more market share.

This News May Hand the Vaccine Market Over to Pfizer and Moderna

The stock price of Moderna Inc (NASDAQ: MRNA) increased 7.84% today. This is why it happened.

MRNA Stock Increased 7.84%: Why It Happened

Aerojet Rocketdyne Holdings

AstraZeneca

Emergent BioSolutions

Jacobs Solutions Inc

Leidos Hld

Lockheed Martin

Much focus on investment comes from the private sector, particularly those of the venture capitalist persuasion. But one of the biggest investors this country has is the federal government.

These Companies Have Seen Large Returns From 2020 Government Investment

American Express

Johnson & Johnson

McDonald's

Snap

It was a jarring start to the week for Wall Street, with stocks in a seeming freefall as a rise in global Covid-19 cases, specifically the delta variant, had many wondering if the smooth economic recovery expected might be too good to be true.

Stocks Headed for Weekly Wins Despite Monday's Rout

It comes after a study on more than 3,700 children.

Moderna's COVID vaccine cleared for 12- to 17-year-olds in EU

Shares of Moderna Inc. gained 4.7% in trading on Friday after the company said that European regulators recommended authorizing its COVID-19 vaccine for teens as young as 12 years old. The European Medicines Agency's Committee for Medicinal Products for Human Use issued the recommendation; next up will be the final decision from the European Commission.

Moderna's stock jumps after announcing its COVID-19 shot is nearing authorization for teens in Europe

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine (Spikevax) for use in adolescents 12 years of age and older. Following the CHMP's positive opinion, the European Commission will consider the vaccine's approval in adolescents.

Moderna's COVID-19 Shot Gets EMA's Backing For Use In Adolescents

CAMBRIDGE, Mass.--(BUSINESS WIRE)--EMA CHMP adopts positive opinion recommending authorization for the use of the Moderna COVID-19 vaccine in adolescents (12-17 years of age) in the EU.

EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of the Moderna COVID-19 Vaccine in Adolescents (12-17 Years of Age) in the European Union

The most important detail investors want to know wasn't revealed.

What Investors Should Know About Moderna's Latest Supply Deal

Novavax

Concerns about the delta variant are rising.

Why BioNTech, Moderna, and Novavax Stocks Soared This Week

Moderna, Pfizer, and Johnson & Johnson are optimistic.

Can Today's Vaccines Beat the Delta Variant?

The company keeps scoring new supply deals across the Pacific.

Why Moderna Topped the Market Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces establishment of new charitable foundation.

Moderna Announces Establishment of New Charitable Foundation

Shares of Moderna Inc. gained 0.3% in trading on Thursday after the company said Taiwan purchased another 35 million doses of its COVID-19 vaccine. The deal could also include Moderna's variant booster shot if and when it is authorized.

Moderna to supply 35 million more doses of its COVID-19 vaccine to Taiwan in 2022 and 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces new supply agreement with Taiwan for 2022 and 2023.

Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna's COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023

News for Moderna Stock (MRNA)